treatment
convalesc
plasma
critic
ill
patient
infect
chest
doi
http
doi
march
novel
sever
acut
respiratori
syndrom
coronaviru
respons
infect
case
death
global
number
still
increas
rapidli
herein
present
four
critic
ill
patient
infect
receiv
support
care
convalesc
plasma
although
four
patient
includ
pregnant
woman
recov
infect
eventu
random
trial
need
elimin
effect
treatment
investig
safeti
efficaci
convalesc
plasma
therapi
sinc
late
decemb
outbreak
novel
sever
acut
respiratori
syndrom
coronaviru
infect
first
appear
wuhan
china
rapidli
spread
countri
march
viru
respons
confirm
case
death
worldwid
date
specif
treatment
recommend
infect
except
meticul
support
care
numer
therapeut
explor
develop
outbreak
recent
trial
show
lopinavirritonavir
treatment
benefit
sever
ill
caus
immunotherapi
virusspecif
antibodi
convalesc
plasma
use
last
resort
improv
surviv
rate
patient
seriou
infecti
diseas
sar
middl
east
respiratori
syndrom
coronaviru
ebola
viru
diseas
pandem
influenza
avianorigin
influenza
previou
report
show
treatment
convalesc
plasma
collat
recov
patient
could
reduc
hospit
stay
mortal
patient
howev
efficaci
convalesc
plasma
critic
ill
patient
infect
remain
unclear
herein
report
diseas
cours
four
critic
ill
patient
treat
support
care
convalesc
plasma
figur
show
clinic
cours
four
critic
ill
patient
infect
first
case
femal
histori
hypertens
present
fever
two
day
clear
sputum
four
day
januari
patient
admit
dongguan
ninth
peopl
hospit
posit
revers
transcriptas
polymeras
chain
reaction
rtpcr
test
throat
swab
dongguan
center
diseas
control
cdc
chest
ct
reveal
bilater
groundglass
opac
primarili
distribut
along
pleura
treatment
arbidol
mg
three
time
daili
lopinavirritonavir
mg
twice
daili
interferon
alpha
inhal
twice
daili
support
therapi
start
pm
februari
patient
oxygen
pressur
decreas
mmhg
oi
mmhg
significantli
increas
consolid
observ
right
lung
patient
transfer
intens
care
unit
icu
dongguan
peopl
hospit
design
center
critic
ill
treatment
februari
receiv
invas
mechan
ventil
apart
antivir
drug
lopinavirritonavir
oseltamivir
interferon
alpha
human
albumin
zadaxin
immunoglobulin
antibacteri
antifung
drug
administr
coinfect
bacteria
aspergillu
pm
show
case
critic
ill
character
respiratori
failur
septic
shock
andor
multipl
organ
dysfunct
failur
around
patient
comorbid
condit
commonli
cardiovascular
diseas
diabet
elderli
peopl
underli
diseas
like
higher
sequenti
organ
failur
assess
score
higher
risk
death
convalesc
plasma
use
last
resort
improv
surviv
rate
patient
sarsinfect
previou
evid
prove
convalesc
plasma
treatment
signific
reduc
rel
risk
mortal
patient
might
antibodi
convalesc
plasma
might
suppress
viraemia
level
neutral
antibodi
donor
plasma
could
import
effect
intervent
howev
level
neutral
antibodi
donor
plasma
transfus
determin
studi
three
patient
test
either
viru
load
antibodi
igm
igg
first
case
viru
load
convalesc
plasma
transfus
significantli
drop
copi
per
millilit
among
four
patient
time
transfus
neg
rtpcr
test
result
rang
day
third
fourth
case
produc
igg
approxim
day
convalesc
plasma
transfus
patient
surviv
critic
ill
diseas
might
mount
higher
antibodi
respons
persist
longer
period
compar
nonsever
diseas
antibodi
level
howev
confound
treatment
antivir
drug
steroid
intraven
immunoglobulin
recent
anim
model
indic
antibodi
produc
infect
could
protect
subsequ
exposur
result
indic
convalesc
plasma
might
potenti
therapi
critic
ill
patient
infect
observ
seriou
advers
reaction
associ
transfus
convalesc
plasma
howev
rel
contribut
support
care
investig
therapi
patient
immunerespons
surviv
could
determin
whether
convalesc
plasma
andor
support
care
provid
clinic
benefit
unknown
safeti
efficaci
convalesc
plasma
transfus
patient
studi
within
context
welldesign
clinic
trial
